GCM
VKTX icon

Gunpowder Capital Management’s Viking Therapeutics VKTX Stock Holding History

Gunpowder Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5K Sell
680
-3,000
-82% -$96.9K 0.02% 188
2026
Q1 		$120K Sell
3,680
-1,000
-21% -$32.1K 0.09% 80
2025
Q4 		$165K Buy
+4,680
New +$166K 0.13% 70

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Gunpowder Capital Management's VKTX Position: Q2 2026 in Review

Gunpowder Capital Management reduced its Viking Therapeutics (VKTX) stake by 82% in Q2 2026, selling an estimated $96.9K and leaving 680 shares worth $26.5K. The position accounts for 0.02% of the portfolio, ranked #188.

Gunpowder Capital Management first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $165K in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Gunpowder Capital Management held 680 shares of Viking Therapeutics worth $26.5K as of Q2 2026.
  • Gunpowder Capital Management sold 3,000 Viking Therapeutics shares in Q2 2026, an estimated $96.9K.
  • Viking Therapeutics made up 0.02% of Gunpowder Capital Management's portfolio in Q2 2026, its #188 holding.
  • Gunpowder Capital Management first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Gunpowder Capital Management's Viking Therapeutics position peaked at $165K in Q4 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Gunpowder Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.